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Abstract
Pulmonary Langerhans’ cell histiocytosis (PLCH) is a rare disorder of unknown cause characterised by the infiltration of the lungs 
and other organs by the bone marrow derived Langerhans’ cells, which carry mutations of BRAF gene and/or NRAS, KRAS and 
MAP2K1 genes. It occurs predominantly in young smokers, without gender predominance. The disease is characterised by for-
mation of eosinophilic granulomas with the presence of Langerhans’ cells infiltrating and destroying distal airways.
High-resolution computed tomography of the chest (HRCT) plays an outstanding role in PLCH diagnosis. The typical radiological 
picture of PLCH is the presence of small intralobular nodules, often forming ‘tree in bud’ lesions, cavitated nodules, thin- and 
thick-walled cystic lesions frequently confluent. Definite diagnosis requires the finding of characteristic lesions in histological 
examination and demonstration of antigen CD1a or CD207 presenting cells in immunohistochemistry. 
Smoking cessation is the most important recommendation for PLCH patients.
There are no evidence based data regarding systemic steroid therapy. The treatment of progressive PLCH is based on cladribine 
or cytarabine as salvage therapy. The prognosis is good, and over 85% of patients survive 10 years.
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Introduction
Pulmonary Langerhans’ cell histiocytosis 
(PLCH) belongs to a group of rare cystic pulmo-
nary diseases, including the following disorders: 
lymphangioleiomyomatosis, Birt-Hogg-Dubé syn-
drome, light chain disease, lymphocytic intersti-
tial pneumonia (Table 1). PLCH is of proliferative 
nature but its pathogenesis is also associated with 
a reactive, inflammatory element [1–3]. 
Definition
Langerhans’ cell histiocytosis is a rare disorder 
of unknown aetiology, caused by clonal prolifera-
tion of Langerhans’ cells (LC), which are geno- and 
phenotypically altered. LC are of myeloid origin and 
over half of them express BRAF V600E oncogene, 
and in 25% of cases, mutations within the NRAS, 
KRAS, MAP2K1 kinase genes are observed. In the 
case of isolated involvement of the lungs in adults 
(pulmonary Langerhans’ cell histiocytosis — PLCH) 
policlonal proliferation of LC occurs with the pres-
ence of significant inflammatory process [1–7]. 
LCH may affect any organ. It takes the form 
of various size nodular lesions, infiltrating and 
damaging the structure of neighboring tissues. 
It affects most commonly the bones, lungs, skin 
and pituitary gland. The involvement of lym-
phopoietic organs (lymph nodes, liver, spleen, 
bone marrow), the alimentary system and central 
nervous system is more frequently observed in 
children. Pulmonary lesions in the course of LCH 
may take isolated forms that anticipate even for 
many years the occurrence of systemic changes, 
or from the very beginning, the lungs may be one 
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Table 1.  The new proposition of clasiffication of  
histiocytic disorders. Histiocytoses of the group L
• Langerhans cell histiocytosis (LCH)
 — LCH SS
 — LCH Lung+
 — LCH MS-RO+
 — LCH MS-RO
 — Associated with other myeloproliferative/ myelodysplastic      
         disorder 
• Intermediate cell histiocytosis (ICH)
• Erdheim-Chester disease (ECD)
 — ECD classical type
 — ECD without bone involvement
 — Associated with other myeloproliferative/ myelodysplastic 
disorder 
 — Extra-cutenous or disseminated JXG with MAP kinase acti-
vating mutation or ALK translocations 
• Mixed ECD and LCH 
SS — single system; MS — multiple system; RO  — risk organ; JXG — 
xanthogranuloma of juvenile type
of several affected organs. The isolated pulmonary 
form of LCH is observed in approximately 50% of 
patients with PLCH [3, 7–12].
In relation to organ involvement, LCH is 
divided into the following forms:
•  single system LCH (SS-LCH) — single- or mul-
tiple-involvement of a single organ or system:
— bones (single bone, single- or multiple, and 
many foci in many bones), 
— the skin,
— the lymph node (excluding the lymph node dra-
ining the area of histiocyte infiltrate) or multiple 
lymph nodes (more than one lymph node group),
— the hypothalamus — hypophysis/the central 
nervous system,
— isolated pulmonary involvement,
— other (the thyroid, thymus, intestines);
•  multisystem LCH (MS-LCH), involvement of 
two or more organs or systems:
— involvement of critical organs (the haemo-
poietic system, spleen, liver and central 
nervous system),
— no involvement of critical organs.
From the point of view of therapeutic deci-
sions, of importance is the involvement of special 
areas and bones that are at risk of involvement 
of the central nervous system. It applies to the 
following bones: vertebrae (possible compression 
spinal fracture and damage to the spinal cord), 
the bones of the orbit, mastoid process, sphenoid 
bone, temporal bones with the transition into the 
soft tissue (possible injury to the nerves of the 
bony face and pituitary gland) [3].
Table 1 shows a new proposal of classification 
of histiocytosis that takes into account overlap-
ping of the disease with myelo/lymphoprolifera-
tive changes and Erdheim-Chester disease. The 
common denominator of this diseases is the pres-
ence of mutations within MAP kinase pathways 
(Fig. 1) [1, 2, 4–6].
Epidemiology
The prevalence of LCH is estimated at 0.5–0.9/ 
/100 000 in children under 15 years of age, and 
0.1/100 000 in people over 15 years of age. The 
persons with PLCH are considered to constitute 
about 5% of patients undergoing open lung biop-
sy. According to Japanese data, the prevalence 
of PLCH in women amounts to 0.07/100,000 and 
0.27/100 000 in men. Due to the nature of the di-
sorder, it is assessed that the prevalence of PLCH 
is underestimated [3, 7–13].
PLCH affects young people in the third and 
fourth decade of life, both men and women.
Over 95% of PLCH patients are tobacco smo-
kers. No relation between the intensity and/or 
duration of smoking and the occurrence of PLCH 
is observed [3, 7–14].
There were cases of isolated pulmonary LCH 
in children, and in the majority of them, the 
disease was associated with passive exposure to 
tobacco smoke.
No genetic predisposition towards LCH was 
found, and familial cases of PLCH occur occasio-
nally [3, 7, 9].
Pathogenesis
Histiocytes belong to a heterogenic group of 
dendritic cells that process and present antigens. 
Langerhans’ cells (LC) are a specific subclass of 
dendritic cells. They are present in the skin, un-
der the epithelium of the bronchial tree and other 
mucosae, and they are first to react to exogenous 
antigens [3, 7]. LC are stimulated by Toll-like re-
ceptors, by bacterial cells or the factors released 
from damaged or wasting away cells. The activated 
LC present antigens and migrate to adjacent lymph 
nodes and induce a cascade of immunological 
response. LC also play a  role in the develop-
ment of tolerance to inhaled harmless antigens, 
thus they protect from excessive inflammatory 
response [7].
Tobacco smoke is considered to be a main factor 
inducing pulmonary form of LCH, but the mecha-
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nisms of the process are unclear. Tobacco smoking 
results in the accumulation of LC in the lungs. 
The phenomenon has been observed in patients 
with PLCH, but also in healthy smokers, people 
with COPD, desquamative interstitial pneumonia 
(DIP) or respiratory bronchitis — interstitial lung 
disease (RB-ILD). Tobacco smoke includes many 
components that induce the production of cytoki-
nes necessary to the recruitment and activation of 
LC. The most important among these cytokines are 
the following: tumour necrosis factor (TNF), granu-
locyte-macrophage colony-stimulating factor (GM
-CSF), transforming growth factor beta (TGF-beta) 
and chemokine of dendritic cells (CCL20) [3, 5].
TNF is produced by macrophages and bron-
chial epithelial cells. It plays a crucial role in acti-
vation and differentiation of LC. Under the influ-
ence of tobacco smoke, bronchial epithelial cells 
and fibroblasts release GM-CSF, which is a strong 
mitogenic factor for LC. Excessive expression of 
this factor within histiocytic infiltrates has been 
shown. Whereas TGF-beta, apart from significant 
proliferative activity towards LC, participates in 
remodelling of the pulmonary parenchyma and 
fibrosis. A potentialising role in LC expansion 
play monocytes, whose recruitment is also related 
to exposure to tobacco smoke [5, 7].
Researches into relationship between tobac-
co smoking and PLCH have shown the presence 
of excessive osteopontin expression in histiocytic 
pulmonary lesions. Osteopontin is a glucoprotein 
with chemokine qualities inducing chemotactic 
activity of macrophages, monocytes and dendritic 
cells, including LC. Moreover, tobacco smoke 
promotes increased expression of anti-apoptotic 
protein Bcl-xL within histiocytic granulomas. 
Activated pathological LC display strong lympho-
stimulating properties and are characterised by 
increased expression of CD40, CD80 and CD86 
antigens. To sum up, tobacco smoke induces in-
flammatory process in the small airways, the rele-
ase of a series of proinflammatory cytokines, and 
the recruitment of macrophages, dendritic cells, 
monocytes, eosinophils and lymphocytes, which 
form inflammatory histiocytic granulomas. The 
process of tissue remodelling, which leads to the 
cystic destruction of the lungs, occurs probably 
due to activation of 2 and 9 metalloproteinases 
produced by dendritic cells, LC and monocytes 
[5, 7, 15]. 
The role of IL-17 in the pathogenesis of hi-
stiocytic lesions is not fully understood. IL-17 is 
a cytokine produced by T cells that participates 
in immunological response to infections, vacci-
ARAF — A-Raf protooncogen; BRAF — B-Raf protooncogen; CRAF — C-Raf protooncogen; GF — growth factor; GFR — 
growth factor recptor; HRAS — Harvey rat sarcoma viral oncogen homolog; KRAS — Kirsten rat sarcoma viral oncogen 
homolog; NRAS — neuroblastoma rat sarcoma viral oncogen homolog; ERK — extracellularsignal-regulated kinases; 
AKT — Akt murine thymoma; MEK — mitogen-activated protein kinase kinase; PIK3 — phosphoinositide kinase 3; 
mTOR — mechanistc target for rapamycin
Figure 1. MEK-ERK signalling cascade of the MAPK pathway and PI3K-AKT pathway. Diagram of RAS proteins activation
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nes and autoimmune diseases. It was shown that 
dendritic cells produce IL-17, which promotes 
the development of giant cells. The reports on 
the concentration of this interleukin in patients 
with PLCH are inconsistent [3, 7].
Pathogenesis of LCH is not established yet, 
and a proliferative or reactive nature of the dise-
ase due to excessive accumulation and apoptosis 
disorders, are still being discussed. It suggests 
that one of the disease mechanisms is accumula-
tion of LC and their longer survival compared to 
proliferation. On the other hand, in pathological 
lesions obtained from children and adults with 
MS-LCH, the features of clonal proliferation 
have been observed, which argue for neoplastic 
nature of the lesions. Clonality is noted in 50% 
of pulmonary lesions, which suggests different 
pathogenesis of pulmonary lesions in adults and 
in children [3, 5].
Nevertheless, identification of the role of 
BRAF mutation in the development of LCH has 
led to a significant shift in the concept of the 
disorder [18]. It is believed that the central core 
of the disease are somatic, heterogenic muta-
tions within MAP kinase pathways (Mitogen 
Activated Protein Kinase) concerning myeloid 
progenitors. MAP kinase regulates the activity 
of many enzymatic proteins and transcription 
factors, and covers a broad spectrum of activity. 
It may impact on the induction of inflammato-
ry processes via recruitment of macrophages/ 
/monocytes, differentiation of T cells, prolife-
ration of smooth muscles and the activation of 
endothelial cells. Mutations within MAP kinase 
pathways concerning precursors to macropha-
ges of distinct origin (bone marrow or yolk bag) 
result in the occurrence of the overlapping syn-
drome of LCH and Erdheim-Chester disease or 
chronic myeloid leukaemia [1, 2, 4, 5, 16]. In 
patients with LCH, activating mutations of the 
BRAF, ARAF, MAP2K1, N/K/HRAS and PIK3CA 
genes have been found [4–6, 16–18]. The scheme 
illustrating signalling pathways involved in 
the control of histiocytic cell proliferation is 
shown in Figure 1. Furthermore, in patients 
with MS-LCH, it has been demonstrated that 
mutation of the BRAFV 600E gene occurs in 
myeloid cells, whereas in patients with SS-LCH, 
mutations are found solely in cells originating 
from infiltrates [19].
Clinical presentation
Symptoms of the disease are associated with 
the location of lesions.
Table 2. Examinations necessary for the evaluation  
of the disease 
1.  Full blood count 
2.  CRP, erythrocyte sedimentation rate
3.  Blood chemistry (electrolytes, creatinine, alkaline phosphata-
se, ALT, AST, bilirubin, total protein, albumin,
4.  Urine examination, morning urine osmolarity 
5.  TSH, LH, FSH, prolactin, oestrogens, testosterone, 
6.  Coagulation tests 
7.  Chest X-ray and CT scans of chest and head 
8.  MRI of brain and pituitary gland
9.  Ultrasound of abdomen, thyroid gland and lymph nodes 
10  Echocardiography, electrocardiogram
11.  PET/CT or low dose whole body CT scan 
12.  Spirometry with bronchodilatation test, body plethysmo-
graphy, diffusion lung capacity, 6 minute walk test 
13.  Bronchoaveolar lavage
All abbreviations in the text
Symptoms from the respiratory system
PLCH patients usually report non-productive 
cough, lowered exercise tolerance, exertional dysp-
noea, fatigue, weight loss and night sweats. Merely in 
6% of patients, haemoptysis is noted. Approximately 
20% of patients do not report any symptoms, and in 
10–30% of individuals, the first sign of the disorder is 
pneumothorax. Pneumothorax occurs in the course 
of the disease in 30–45% of cases. Symptoms arise 
6–12 months prior to the recognition of the disorder 
but in some individuals, diagnosis is established after 
many years of observation. Dyspnoea at rest and the 
features of right-ventricular circulatory failure occur 
at late stages of the condition [3, 7–12]. More than 
10% of PLCH patients develop pulmonary hyper-
tension. It is not always related to the exacerbation 
of pulmonary lesions, and may be the effect of the 
involvement of pulmonary vessels observed in the 
course of the disease [3, 7–12, 20, 21].
Physical examination often does not detect 
significant pathological signs. The most frequen-
tly heard are the following: weakened vesicular 
murmur, wheezes and dry rales, and in the case 
of pneumothorax, the symptoms thereof. 
In the course of LCH, a broad spectrum of 
organic lesions is observed, thus the need for tho-
rough clinical work-up is highlighted [3]. Table 
2 illustrates the scope of examinations necessary 
for initial evaluation of LCH patients.
Skin lesions
They usually take the form of red, brown and 
hard nodules, which repeatedly spontaneously 
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Figure 2. Histiocytic lesions on scalp, fingers and nails
regress leaving a central depression. On the hairy 
skin of the head, trunk and the bending areas, 
erythemic and pustular alterations may appear, 
which resemble follicular ichthyosis or acne 
changes. Involvement of the nails and nailfolds 
may also appear [3, 22] (Fig. 2). 
Bone lesions — over 50% of isolated bone 
lesions concern children under 5 years of age. 
Changes in the form of painful osteolytic defects 
and nodulated masses spreading to the soft tis-
sues are usually discovered in the cranial vault, 
bony face, particularly in the lower jaw, orbital 
bones, mastoid process, ribs, shoulder-blade and 
pelvis. Of particular danger is the involvement of 
the bones of the spinal column, the base of the 
scull and orbit, which is signaled by the pres-
sure and damage to the surrounding structures 
(Figs 3–5) [3, 23].
The hypophysis — in about 10–20% of adults 
at various stages of the disorder, damage to the 
posterior lobe of the hypophysis in the form of di-
abetes insipidus is observed. Affected hypophysis 
frequently manifests itself in clinical symptoms 
and endocrynological disorders without changes 
seen on imaging tests, including magnetic reso-
nance. Panhypopituitarism is rarely noted, but 
some individuals experience hormonal disorders 
[3, 7–11].
LCH may affect any organ: the thyroid, thy-
mus, lymph nodes, intestines, reproductive 
organs. A specific form is the involvement of the 
liver in the form of cholangitis sclerosans [3].
Radiological findings
Table 1 shows essential radiological tests 
assessing particular systems that may be affected 
by the condition.
Figure 3. Osteolytic lesions in mandible — the picture of floating 
tooths
Rycina 4. Osteolitic lesions in bones of scalp. Condition after surgical 
resection of parietal lesions (courtesy of dr I. Bestry)
Figure 5. MRI — histiocytic infiltration in the region of the right orbit 
(courtesy of dr K. Błasińska-Przerwa)
Advances in Respiratory Medicine 2017, vol. 85, no. 5, pages 277–289 
282 www.journals.viamedica.pl
Due to the commonest localisation of the 
lesions, of particular interest is the evaluation of 
the skeletal system, the lungs and hypophysis. 
To assess the extent and activity of the disease, 
if available, PET/CT is recommended. In the re-
maining cases, low-dose CT of the entire skeleton 
is suggested [3, 7–13, 24, 25].
Chest radiograph
The value of standard chest radiograph is 
limited as multiple lesions are small and difficult 
to notice. In patients with advanced disease, 
nodular, reticular, and cystic lesions are visible 
in the middle and upper lung fields (Fig. 6). Lung 
volumes are usually normal or increased. Pleural 
lesions due to past pneumothorax are frequently 
observed. Moreover, enlargement of the hilar or 
mediastinal lymph nodes may occur [3, 7–12, 
24–26].
Computed tomography
Computed tomography, in particular high-res-
olution computed tomography, is important in 
diagnosis of histiocystic lesions, especially in 
the case of the lungs [26]. The most often noted 
lesions are centrilobular nodules, frequently 
forming ‘tree-in-bud’ appearance, nodules with 
or without a lacuna, initially thick-walled cysts 
of various shape, which may be isolated or con-
fluent with the appearance of “clover leaves”. 
As the disease evolves, the cysts become bigger 
Figure 6. Chest X-ray — bilateral small cysts, partially confluent 
nodules predominate in the upper and middle lung fields. There is 
opacity in the right costophrenic angle due to previous pneumothorax 
(courtesy of dr I. Bestry) 
Figure 7. High resolution computed tomography — small intralobular 
nodules in both lung fields (courtesy of dr I. Bestry)
Figure 8. High resolution computed tomography – multiple nodules 
and cysts with thick walls, partially confluent (courtesy of dr I. Bestry)
and thin-walled. In the majority of adult patients 
(over 90%), the costophrenic angles are spared 
(Figs 7–9). Whereas in children, both lungs are 
symmetrically affected, lesions are found even 
in the lower lobes. In addition, pneumothorax 
is commonly present [24, 25]. In elderly heavy 
tobacco smokers, apart from lesions associated 
with PLCH, the features of COPD may be visi-
ble, including emphysematous bullae. Enlarged 
lymph nodes may be present. In patients with 
pulmonary hypertension, megalocardia and 
enlarged pulmonary trunk are observed [3, 27].
Positron emission tomography
PET with fluorodeoxyglucose (FDG) is more 
sensitive than CT in identifying bone lesions, in 
particular those subclinical, in the lungs, lymph 
nodes, liver, spleen or thyroid. PET is particularly 
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sorders. In the remaining cases, obstruction with 
the features of pulmonary hyperinflation, often 
partially reversible, predominates. Lower vital 
capacity and total lung capacity are rarely repor-
ted, and affect mainly individuals with recurrent 
pneumothorax and pleurodesis. The commonest 
abnormality is reduced diffuse capacity of the 
lung for carbon monoxide, which is observed in 
about 70–90% of persons. 
6-minute walk test (6MWT) helps to observe 
desaturation during exercise, and at advanced 
stages of the disease — a reduced walk distance 
[3, 7–12, 24, 25].
Bronchoscopy and bronchoalveolar lavage
Bronchoscopy does not reveal features ty-
pical of PLCH. The examination is performed 
in order to exclude other disorders, especially 
infections. The importance of transbronchial 
biopsy is limited and estimated at 10–50%, 
which is caused mainly by uneven distribution 
of lesions [29]. It is the most useful in the case 
of patients with nodular lesions seen on chest 
x-ray. Furthermore, there is a high probability 
of complication with pneumothorax during the 
procedure, in particular in subjects with exten-
sive cysts. Elevated, over than 5% cells display 
CD1a expression in BAL with typical radiologi-
cal pattern seen on chest HRCT is indicative of 
PLCH. However, only 10–20% of patients with 
PLCH show this pattern of findings. Elevated 
count of CD1a positive cells in BAL is not fully 
pathognomonic for PLCH as it may be found in 
healthy tobacco smokers, COPD patients and in 
the course of pulmonary fibrosis [30, 31].
Open lung biopsy
Open lung biopsy is often the necessary 
examination to definitely identify PLCH. Speci-
mens should be taken from sites at which HRCT 
shows an abundance of nodules. When LCH has 
been confirmed by histological examination of 
specimens obtained from other foci (skin, bones), 
typical of the disease pulmonary lesions do not 
need to be additionally verified during biopsy [3].
Histological examination
The lungs of PLCH patients are marked with 
cystic and nodular lesions with a diameter up 
to 15 mm. In advanced forms of the condition, 
nodules retrogress and cysts are formed and 
pulmonary distension increases. The biggest ac-
cumulation of lesions is found in the upper and 
middle lung fields, and the costophrenic angles 
in 90% of cases remain unaffected [3, 16].
Figure 9A, B. High resolution computed tomography- multiple cysts, 
which predominate in the upper and middle lung zones with sparing of 
the costophrenic angles (courtesy of dr I. Bestry)
A
B
useful at early nodular stages of the condition, in 
the cases with the presence of thick-walled lacu-
nae and in patients with MS-LCH [3]. Basing on 
the results observed in the group of 44 patients 
(41 children, 3 adults), Phillips et al. [28] have 
shown that PET is more sensitive imaging test asses-
sing an early reaction to the applied treatment and 
early recurrence. However, PET has its limitations 
— it does not differ inflammatory and neoplastic 
changes from histiocytic pulmonary infiltrates.
Laboratory tests
In LCH patients, elevated serum inflammato-
ry markers level is found. In case of patients with 
diabetes insipidus, serum hyperosmolarity with 
lower urine specific weight and its hyposmola-
rity are observed. Lesions in the liver manifest 
themselves in elevated hepatic enzymes concen-
tration, in particular intrahepatic cholestasis and 
increased bilirubin level [3]. 
Pulmonary function testing
Patients with PLCH suffer from various ven-
tilation disturbances. Initially, approximately 1/5 
of patients do not have pulmonary function di-
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Initially inflammatory process with formation 
of granulomas takes place near small bronchi and 
bronchioles, extending to a varying degree into ad-
jacent lung parenchyma. The presence of pigment-
ed macrophages is frequently identified. In some 
cases, apart from the bronchiole-centred lesions, 
vascular alterations in the arterial and venous part 
of the vascular bed may be observed. Typical of the 
condition cysts develop in peribronchial space, 
where, apart from destroying granulomas, the 
bronchiole wall is destructed and the bronchioles 
are dilated. In consequence, polymorphic cystic 
formations appear with possible emphysematous 
changes and distension. Moreover, during fibrosis, 
stellar scars and fibrotic rings around the bronchi-
oles are formed [7, 12, 29, 32].
At early stages of the disease, microscopic 
examination shows predominating poorly formed 
inflammatory nodules located in peribronchial 
spaces. Then, the inflammatory infiltrate extends 
into interalveolar spaces and blurs the lung archi-
tecture. Nodules contain a mixture of inflammato-
ry cells, such as T cells, macrophages, monocytes 
and LC. Langerhans’ cells are relatively large, 
with a pale cytoplasm and a convoluted nucleus 
with a  longitudinal crease resembling a coffee 
grain. Electron microscopic evaluation shows in 
cytoplasm the so-called Birbeck granules, which 
are pathognomonic for LC. They are pentalam-
inar structures associated with cell membrane 
consisting of lectin. They may be also found in 
immunohistochemical examination using anti-
bodies against langerin, i.e. antigen anti- CD207. 
LCs show expression of the S protein and CD1a 
antigen, whose detection is crucial for diagnosis 
(Figs 10–12). The structure of inflammatory gran-
ulomas varies, even within the same lung speci-
men. In advanced disease, in the central part of 
the nodule, a lacuna is formed, which is probably 
the part of the remaining lumen of the bronchiole 
or the effect of destruction mediated by cytokines 
and metalloproteinases. The bronchiole-centred 
lesions evolve forming symmetric stellar scars. 
Histiocytic granulomas may go along with pul-
monary lesions, e.g. organising inflammation or 
lesions associated with tobacco smoke exposure, 
such as bronchiolitis, desquamative interstitial 
pneumonia, respiratory bronchiolitis with accom-
panying interstitial lung disease or emphysema.
In advanced disease, LCs are less abundant 
and the cystic and fibrotic pattern predominates.
In addition, in PLCH patients, internal wall of 
the vessels is thickened, both in the arteries and 
veins, which subsequently, results in pulmonary 
hypertension.
Figure 10. Langerhans cell histiocytosis. Low magnification view 
showing discrete nodular infiltration within lung parenchyma with the 
presence of central cavity (H+E × 200) (Courtesy of Prof. R. Langfort)
Figure 11. Langerhans cell histiocytosis. Large histiocytes with folded 
nuclei and few mitotic figures (H+E × 400) (Courtesy of Prof. R. 
Langfort)
Rycina 12. Immunohistochemistry for CD1a demonstrating strong 
positive staining in Langerhans cells (magn. × 200) (Courtesy of Prof. 
R. Langfort)
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The patients qualified for targeted therapy 
need to be tested for mutations within the BRAF, 
ARAS, NRAS, KRAS and MAP2K genes [16–19]. 
Moreover, a novel diagnostic technique used in 
monitoring of treatment with BRAF inhibitors, is 
the analysis of the BRAF V600E gene mutation in 
circulating serum DNA [17]. 
Diagnosis
Diagnosis of LCH should be based on clinical 
and radiological tests, but the most important is 
histological assessment with immunohistoche-
mical testing.
The definite diagnosis of LCH depends on 
adequate clinical presentation and the identifi-
cation of Langerhans’ cells in the biopsy material 
visible in electron microscopic visualisation, 
which show the presence of one of the following 
antigens: CD 207 (langerin), CD1a or Birbeck 
granules.
The tentative diagnosis of PLCH relies on 
adequate clinical presentation confirmed radiolo-
gically (chest CT scan reveals cysts and nodules 
seen mainly in the upper and middle lung fields). 
However, any suspicious lesion found should 
be confirmed with histological examination.
Diagnosis needs to be validated with histo-
logical technique, in particular in patients with 
recommendations for systemic treatment [3, 33].
Differential diagnosis
Table 3 illustrates the list of disorders that 
should be taken into account while diagnosing 
the patients with cystic pulmonary lesions. In ad-
dition, special attention should be paid to people 
with solitary nodular lesions. As in such cases, 
the list of the reasons for the observed alterations 
may be longer, and may include sarcoidosis, hy-
persensitivity pneumonitis or infections.
Treatment
Treatment of LCH depends on the spread of 
the disease, affected organs, including lesions in 
critical organs and the degree of damage. 
Smoking cessation
In case of patients with isolated pulmonary 
LCH (PLCH), the first recommendation is smoking 
cessation and detailed evaluation of the disease 
dynamics. In about 50% of PLCH patients, such 
approach leads to partial regression with a sub-
sequent stabilisation of the disorder [3, 7–13, 20, 
33–35]. To date no biological markers were found 
Table 3. Diseases with cystic pattern of lung lesions
• Lymphangioleyomatosis (LAM)
 — Sporadic LAM
 — Tuberous sclerosis complex LAM
• Pulmonary Langerhans cell histiocytosis
• Erdheim-Chester disease
• Birt-Hogg-Dubé disease
• Lymphatic disorders
 — Lymphoid interstitial pneumonia
 — Light chain disease
 — Amyloidosis
 — Hyper-IgE syndrome
• Genetic disorders
 — Ehlers-Danlos syndrome
 — Neurofibromatosis
 — Marfan syndrome
 — Proteus syndrome
• Congenital cystic adenomatoid malformations
• Respiratory papillomatosis
• Pneumocistis jiroveci
identifying the patients for whom such conduct 
was sufficient and the patients in whom, apart from 
smoking cessation, the disease progressed [13].
Systemic chemotherapy
Systemic chemotherapy is recommended in 
the cases of MS-LCH, with or without the involve-
ment of critical organs, SS-LCH with multiple 
lesions and SS-LCH with lesions in specific sites. 
There is no established standard of chemothe-
rapy to date. Although in children chemotherapy 
with vinblastine and prednisone proved to be 
effective, the results of treatment in adults tur-
ned out to be less successful [3, 7–13, 33–41]. In 
patients with multiple bone lesions and affected 
lungs, significantly higher effectiveness of tre-
atment with cytarabine or cladribine compared 
to vinblastine and prednisone has been shown.
Glucocorticosteroids
Some authors recommend systemic steroid 
therapy in case of intensive symptoms from the 
respiratory system, in particular in patients with 
pulmonary nodular lesions. 1 mg/kg of prednisone 
per month with gradual reduction of a dose is 
suggested, so as the treatment does not exceed 
6 months. Such therapy has not been confirmed 
by clinical trials, and recently its harmful effect 
have been underlined [3]. 
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Chemotherapy
Basing on extrapolated observations made 
during randomised trials in children, various 
types of cytoreductive therapy (methotrexate, 
vinblastine, 6 mercaptopurine, etoposide) have 
been applied in adult LCH patients [3, 42–49]. 
However, the disease in adults runs a diverse 
clinical course and many drugs are differently 
tolerated. Tazi et al. [48] in a retrospective study 
assessed the therapy with vinblastine and stero-
ids in 35 LCH adults, including 17 patients with 
pulmonary involvement. 70% of the subjects 
responded to the treatment but in more than 40% 
of patients, recurrence of the disease occurred 
within 5-year follow-up. The improvement in 
ventilation parameters due to applied treatment 
has not been noted in any case. In the group of 
58 adult subjects with histiocytosis with multiple 
bone involvement, including 28% of patients with 
pulmonary involvement, Cantu et al. [38] have 
shown higher effectiveness of treatment with 
cladribine and cytarabine compared to vinblasti-
ne [38]. In the case of aggressive course of PLCH, 
6 cycles of cladribine in the form of intravenous 
infusions, at a dose of 6 mg/m2 per 5 days every 
4 weeks is recommended. Effectiveness of the 
therapy is evaluated to exceed 75%.
In the case of progression after cladribine, 
salvage therapy is cytarabine administered at 
a dose of 100mg/m2 per 5 consecutive days every 
4 weeks. If the treatment is effective, next 6 cyc-
les are administered. Another drug that proved 
to be effective as salvage therapy in children is 
clofarabine [3].
Vemurafenib and other BRAF inhibitors
These drugs offer new possibilities for targe-
ted LCH therapy in patients with relevant muta-
tions. The number of reports on these therapies 
is constantly increasing. The treatment seems to 
be effective but it does not fully eliminate LC, 
and discontinuation of treatment results in the 
disease progression [5, 18].
The researches conducted among French 
LCH children have shown that detection of BRAF 
mutation was associated with a weaker response 
not only to the first-line treatment (vinblastine 
and steroids) but also a weaker response to a se-
cond-line treatment and a higher proportion of 
recurrence [16, 19, 49].
MAP kinase inhibitors
Sorafenib, trametinib and cobimetinib have 
been reported to be effective in patients with 
aggressive form of histiocytosis. Furthermore, it 
is vital to remember that presented mutations in 
Langerhans’ cells are not excluding mutations, 
thus, in particular cases, there are recommenda-
tions to apply double targeted therapy [10, 16]. 
Single cases of the disease regression after 
the use of imatinib (tyrosine kinase blocker) have 
been reported [5]. 
Pneumothorax
In approximately 10-30% of patients, 
pneumothorax is the first symptom of the con-
dition. It has been demonstrated that these per-
sons have a greater probability of a consecutive 
recurrence. Moreover, this group often includes 
young men who smoke relatively less cigarettes 
and whose lung function is more affected by the 
disease. Taking into consideration the above data 
and clinical and financial effectiveness of HRCT 
in identifying PLCH patients, recommendation of 
HRCT in the case of the individual with sponta-
neous pneumothorax seems to be justified [24–26]. 
Pleurodesis is proposed in the case of re-
currence of pneumothorax and concerns about 
50% of patients in whom it occurred. It does not 
constitute a  contraindication to possible lung 
transplantation [3].
Treatment of pulmonary hypertension
Pulmonary hypertension in the course of 
PLCH may be the consequence of progressive 
destruction of lung parenchyma, but in a  lower 
proportion of cases, it also develops in the pa-
tients with stable ventilation parameters. Thus, 
to assess pressure in the pulmonary artery, echo-
cardiography is advised. A positive result of drugs 
lowering blood pressure in the pulmonary artery, 
including inhibitors for phosphodiesterase and 
endothelin receptor in PLCH patients developing 
pulmonary hypertension has been observed. Tre-
atment with prostacyclin should be applied with 
caution and mainly in patients with the features 
of venous changes (veno-occlusive disease, VOD), 
for episodes of severe pulmonary oedema in people 
using this drug have been documented. However, 
the main remedy is oxygen therapy and a possible 
and careful anticoagulation treatment [3, 21].
Lung transplantation
In patients with significantly damaged ven-
tilatory function of the lungs, with the features 
of respiratory failure and those developing pul-
monary hypertension, lung transplantation is an 
ultimate therapeutic option. Pulmonary hyper-
tension is noted in 80–90% of subjects qualified 
for transplantation and constitutes an important 
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risk factor of the procedure. Prognosis of patients 
undergoing transplantation does not differ signi-
ficantly from the individuals who undergo the 
procedure due to lymphangioleiomyomatosis or 
emphysema. Nearly 75% of patients survive 1 
year, and more than 50% — 5 years. Poorer progno-
sis after transplantation is carried by people with 
MS-LCH. In about 1/5 of cases, recurrence of LCH 
in the transplanted organ has been found [3, 5].
Treatment of bone lesions
In some cases with solitary bone involve-
ment, surgical removal of the focus is proposed 
or treatment of lesions with steroid injections. 
Patients with multiple bone lesions are treated 
systemically, surgically and/or with biphospho-
nates [3, 38, 40]. 
Hormone replacement therapy
Moreover, in patients with endocrinologic 
dysfunction, replacement therapy is recommen-
ded, with appropriate clinical, biochemical, 
enzymatic and hormone parameters being con-
trolled [3].
Follow-up examination
The first follow-up examination should be 
performed after 3 months. The consecutive con-
trols should depend on the disease activity and 
its advancement, but they should be performed 
at least every 3–12 months. It has been shown 
that people with isolated pulmonary histiocyto-
sis during follow-up examinations do not need 
to have assessed many organs, and HRCT has 
a limited value in terms of the evaluation of the 
disorder dynamics. Of importance is the assess-
ment of pulmonary functioning. As the patients 
are tobacco dependent, their participation in 
tobacco therapy programmes is highly recom-
mended [3, 21, 29]. Tazi et al. [50] have shown 
that PLCH patients do not need to undergo x-ray 
examination of the lungs or bones every year, but 
only in the case of the occurrence of new signs. 
But the authors recommend constant monitoring 
of pulmonary function testing.
Prognosis
The natural course and prognosis of PLCH 
are unpredictable. It has been shown that PLCH 
patients have lower mean survival compared 
to people of the same sex and age [8]. Approxi-
mately 50% of patients experience spontaneous 
regression of the disease with improvement or 
stabilisation of the ventilation parameters only 
after smoking cessation [3, 29, 32, 34]. In the re-
maining cases, the disorder gradually progresses, 
both in the lungs and in other organs. A lowered 
DLCO with stable ventilation parameters suggests 
increasing pulmonary hypertension and constitu-
tes an indication to cardiac catheterisation. The 
presence of pulmonary hypertension worsens 
prognosis.
Tazi et al. [20] have demonstrated that the 
factors that impair prognosis in PLCH patients 
are age, exacerbation of obstruction, lowered Pa02, 
a higher score obtained in SGRQ (St. George’s Re-
spiratory Questionnaire) and continued tobacco 
smoking (HR-3.28). An adverse effect on prog-
nosis has the involvement of other organs [20].
A significant impact on the disease course have 
coexisting infections, which may lead to death. 
LCH promotes the development of other 
neoplasms originating from the lymphatic and 
haemopoietic systems, including LCH overlap-
ping with chronic myelogenous leukaemia . The 
condition also predisposes to developing lung 
cancer [1, 3, 5].
Pregnancy and labour
PLCH affects mainly young people, therefore, 
the approach during pregnancy and labour is 
crucial. Generally, pregnancy was not found to 
worsen the course of PLCH or diabetes insipidus. 
Undoubtedly, particular attention should be paid 
during perinatal period, and due to a  greater 
probability of pneumothorax, caesarean section 
should be used [3, 51]. 
Conclusion
1. Langerhans’ cell histiocytosis (LCH) is a rare 
disorder of unknown aetiology, caused by 
clonal proliferation of geno- and phenotypi-
cally altered Langerhans’ cells (LC).
2. LCH may affect any organ. It usually involves 
the bones, lungs, skin and pituitary, lymph-
opoietic organs (lymph nodes, liver, spleen, 
bone marrow), alimentary system, thyroid 
and CNS.
3. Pulmonary lesions in the course of LCH may 
be as follows: isolated, anticipating even 
for many years the occurrence of systemic 
changes, or from the very beginning, the 
lungs may be one of the sites involved. 
4. Tobacco smoke is a main causative factor for 
PLCH, and smoking cessation is the most 
vital recommendation.
5. Chest high resolution computed tomogra-
phy is of particular importance in imaging 
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of histiocytic lesions, and the commonest 
pulmonary lesions are the following: cen-
trilobular nodules, nodules with or without 
a central cavity, initially thick-walled cysts 
of various shape that may convolute forming 
the so-called clover leaves. As the disease 
evolves, cysts become bigger and thin-walled. 
In the majority of patients (over 90%), the 
costophrenic angles are not affected by the 
disorder.
6. The definite diagnosis of PLCH relies on 
adequate clinical presentation and the identi-
fication of Langerhans’ cells in the examined 
material showing on the immunohistochem-
istry the presence of one of the following 
antigens: CD207 (langerin), CD1a or on the 
electron microscopic visualisation of Birbeck 
granules.
7. The presence of elevated by 5% the cells 
expressing CD1a antigen in BAL fluid, with 
typical radiological presentation visible 
on chest HRCT speaks in favour of PLCH 
diagnosis.
8. Treatment of LCH depends on the spread 
of the condition, involvement of organs, in-
cluding alterations to critical organs and the 
degree of damage. Currently, the preferred 
cytostatic treatment option includes cladrib-
ine or cytarabine. In patients with isolated 
pulmonary involvement leading to respira-
tory insufficiency, lung transplantation is 
recommended.
9. PLCH patients have lower mean survival than 
individuals of the same sex and age. Adverse 
prognostic factors include as follows: age, tobac-
co smoking, severe obstruction, lowered PaO2, 
a higher score in SGRQ, pulmonary hyperten-
sion and the multiple organ involvement.
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